RyanCassadayMD

PubMed

• 1 citations
  Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL.
  Ibrahim Aldoss, Gregory W Roloff, Rawan Faramand, Noam E Kopmar, Chenyu Lin
  Blood Advances. 2024-12-10
• Development and validation of predictive models of early immune effector cell-associated hematotoxicity (eIPMs).
  Emily C Liang, Jennifer J Huang, Andrew J Portuguese, Valentín Ortiz-Maldonado, Aya Albittar
  Blood Advances. 2024-12-03
• 1 citations
  Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.
  Gregory W Roloff, Ibrahim Aldoss, Noam E Kopmar, Chenyu Lin, Simone E Dekker
  Journal of Clinical Oncology. 2024-10-17

Journal Articles

• Phase 1/2 Trial of Cladribine, High-Dose Cytarabine, Mitoxantrone, and G-CSF with Dose-Escalated Mitoxantrone for relapsed/refractory Acute Myeloid Leukemia or Other H...  
  Kelda M Gardner, Vivian G Oehler, Heather A Smith, Anna B Halpern, Paul C Hendrie, Sarah A Buckley, Roland B Walter, Pamela S Becker, Ryan D Cassaday, Asma Anwar, Bart..., Haematologica

Abstracts/Posters

• Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories
  Ryan D. Cassaday, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) ...
  Ryan D. Cassaday, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Multi-Omic Precision Medicine Clinical Trial in Acute Leukemia
  Ryan D. Cassaday, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) ...
  Ryan D. Cassaday, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Low Achievement of End of Life Quality Measures in Large B-Cell Lymphoma Patients Who Progressed after CD19-Specific CAR-T Cell Therapy
  Ryan D. Cassaday, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase II, Multicenter Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed By Maintenance Therapy with Romidepsin for T-Cell Lymphoma
  Ryan D. Cassaday, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Factors Associated with Response, CAR-T Cell In Vivo Expansion, and Progression-Free Survival after Repeat Infusions of CD19 CAR-T CellsClinically Relevant Abstract
  Ryan D. Cassaday, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Impact of Lab Abnormalities at the Time of Progression in Patients Receiving CD19-Specific CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphomas
  Ryan D. Cassaday, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Final Results from a Prospective Phase II Study
  Ryan D. Cassaday, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Outcomes of Patients with Large B-Cell Lymphomas and Progressive Disease Following CD19-Specific CAR T-Cell TherapyClinically Relevant Abstract 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) Is Active and Well-Tolerated in Adults with Newly-Diagnosed Acute Lympho... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Factors Impacting Progression-Free Survival after CD19-Specific CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Immunotherapy with T-Cells Engineered with a Chimeric Antigen Receptor Bearing a Human CD19-Binding Single Chain Variable Fragment for Relapsed or Refractory Acute Lym... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Pembrolizumab in Combination with Standard RCHOP Therapy for Previously Untreated Diffuse Large B-Cell Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Extensive safety profile of inotuzumab ozogamicin (InO) in relapsed/refractory acute lymphoblastic leukemia (ALL) patients enrolled in the phase 3 INO-VATE trial. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Join now to see all